AAM Urges Action On Product Hopping And Patent Thickets

The AAM’s senior vice-president, Jeffrey Francer, has offered suggestions to US lawmakers on how to curb anti-competitive tactics used by originators.

Red_Arrow_Stethoscope
The AAM’s Jeffrey Francer has thrown light on how originators game the system • Source: Shutterstock

The Association for Accessible Medicines has urged US lawmakers to take action on originator tactics used to “game the system”, including ‘product hopping’ and biosimilar patent thickets used to deter competition.

Testifying before a House of Representatives subcommittee on consumer protection and commerce, AAM senior vice-president Jeffrey Francer said that “current...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.